Gregory J. Gerstner

Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy

Tumor biomarkers for diagnosis, prognosis and targeted therapy

S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial